FDA grants EUA for PathogenDx COVID-19 test

By LabPulse.com staff writers

April 27, 2021 -- The U.S. Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) to PathogenDx for the company's microarray-based COVID-19 test, DetectX-Rv.

DetectX-Rv is a reverse transcription polymerase chain reaction (RT-PCR) and DNA microarray test that uses material from nasopharyngeal, oropharyngeal, midturbinate, and anterior nasal swabs, as well as nasal aspirates, nasopharyngeal wash/aspirates, and bronchoalveolar lavage specimens from patients with suspected COVID-19, according to the firm.


Copyright © 2021 LabPulse.com
 

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?